CD4 and neoplasm: Recent reports showing that immunotherapy with checkpoint inhibitors such as Ipilimumab can activate pre-existing and de novo B cell responses [1], in addition to de novo CD4+ T cell responses [13], have served to underline the ongoing clinical relevance of achieving a broader understanding of the role of T-B collaboration in anti-tumor immunity.